APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiretroviral Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antiretroviral Drug Market Outlook and Growth Opportunities 2026

22 December 2025197 pages

Choose your research edition.

Industry ResearchAntiretroviral Drug Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiretroviral Drug Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Antiretroviral Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiretroviral Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiretroviral Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Antiretroviral Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antiretroviral Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antiretroviral Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antiretroviral Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antiretroviral Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antiretroviral Drug market include Boehringer-Ingelheim, Bristol-Myer Squibb, CIPLA, Gilead Sciences, ViiV Healthcare, AbbVie, Merck and Johnson and Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Antiretroviral Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antiretroviral Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antiretroviral Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antiretroviral Drug market.

Antiretroviral Drug Segment by Company

Boehringer-Ingelheim

Bristol-Myer Squibb

CIPLA

Gilead Sciences

ViiV Healthcare

AbbVie

Merck

Johnson and Johnson

Antiretroviral Drug Segment by Type

Multi-Class Drugs Combination

Protease Inhibitors

NRTI

NNRTI

Other

Antiretroviral Drug Segment by Application

Hospital

Pharmaceutical Companies

Other

Antiretroviral Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antiretroviral Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Antiretroviral Drug key companies, revenue, market share, and recent developments.

3. To split the Antiretroviral Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Antiretroviral Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antiretroviral Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Antiretroviral Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiretroviral Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiretroviral Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiretroviral Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antiretroviral Drug industry.

Chapter 3: Detailed analysis of Antiretroviral Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Antiretroviral Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Antiretroviral Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antiretroviral Drug Industry Trends Table 2. Antiretroviral Drug Industry Drivers Table 3. Antiretroviral Drug Industry Opportunities and Challenges Table 4. Antiretroviral Drug Industry Restraints Table 5. Global Antiretroviral Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antiretroviral Drug Revenue Share by Company (2021-2026) Table 7. Global Antiretroviral Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Antiretroviral Drug Key Company Manufacturing Base & Headquarters Table 9. Global Antiretroviral Drug Company, Product Type & Application Table 10. Global Antiretroviral Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Antiretroviral Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Multi-Class Drugs Combination Table 15. Significant Companies of Protease Inhibitors Table 16. Significant Companies of NRTI Table 17. Significant Companies of NNRTI Table 18. Significant Companies of Other Table 19. Global Antiretroviral Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Antiretroviral Drug Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Antiretroviral Drug Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Antiretroviral Drug Sales Value Share by Type (2021-2026) Table 23. Global Antiretroviral Drug Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital Table 25. Significant Companies of Pharmaceutical Companies Table 26. Significant Companies of Other Table 27. Global Antiretroviral Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Antiretroviral Drug Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Antiretroviral Drug Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Antiretroviral Drug Sales Value Share by Application (2021-2026) Table 31. Global Antiretroviral Drug Sales Value Share by Application (2027-2032) Table 32. Global Antiretroviral Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Antiretroviral Drug Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Antiretroviral Drug Sales Value Share by Region (2021-2026) Table 35. Global Antiretroviral Drug Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Antiretroviral Drug Sales Value Share by Region (2027-2032) Table 37. Global Antiretroviral Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Antiretroviral Drug Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Antiretroviral Drug Sales Value Market Share by Country (2021-2026) Table 40. Global Antiretroviral Drug Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Antiretroviral Drug Sales Value Market Share by Country (2027-2032) Table 42. Boehringer-Ingelheim Company Information Table 43. Boehringer-Ingelheim Business Overview Table 44. Boehringer-Ingelheim Antiretroviral Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Boehringer-Ingelheim Antiretroviral Drug Product Portfolio Table 46. Boehringer-Ingelheim Recent Development Table 47. Bristol-Myer Squibb Company Information Table 48. Bristol-Myer Squibb Business Overview Table 49. Bristol-Myer Squibb Antiretroviral Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Bristol-Myer Squibb Antiretroviral Drug Product Portfolio Table 51. Bristol-Myer Squibb Recent Development Table 52. CIPLA Company Information Table 53. CIPLA Business Overview Table 54. CIPLA Antiretroviral Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. CIPLA Antiretroviral Drug Product Portfolio Table 56. CIPLA Recent Development Table 57. Gilead Sciences Company Information Table 58. Gilead Sciences Business Overview Table 59. Gilead Sciences Antiretroviral Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Gilead Sciences Antiretroviral Drug Product Portfolio Table 61. Gilead Sciences Recent Development Table 62. ViiV Healthcare Company Information Table 63. ViiV Healthcare Business Overview Table 64. ViiV Healthcare Antiretroviral Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. ViiV Healthcare Antiretroviral Drug Product Portfolio Table 66. ViiV Healthcare Recent Development Table 67. AbbVie Company Information Table 68. AbbVie Business Overview Table 69. AbbVie Antiretroviral Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. AbbVie Antiretroviral Drug Product Portfolio Table 71. AbbVie Recent Development Table 72. Merck Company Information Table 73. Merck Business Overview Table 74. Merck Antiretroviral Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Merck Antiretroviral Drug Product Portfolio Table 76. Merck Recent Development Table 77. Johnson and Johnson Company Information Table 78. Johnson and Johnson Business Overview Table 79. Johnson and Johnson Antiretroviral Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Johnson and Johnson Antiretroviral Drug Product Portfolio Table 81. Johnson and Johnson Recent Development Table 82. Research Programs/Design for This Report Table 83. Authors List of This Report Table 84. Secondary Sources Table 85. Primary Sources List of Figures Figure 1. Antiretroviral Drug Product Image Figure 2. Global Antiretroviral Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiretroviral Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Antiretroviral Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Multi-Class Drugs Combination Image Figure 8. Protease Inhibitors Image Figure 9. NRTI Image Figure 10. NNRTI Image Figure 11. Other Image Figure 12. Global Antiretroviral Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Antiretroviral Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Antiretroviral Drug Sales Value Share by Type (2021-2032) Figure 15. Hospital Image Figure 16. Pharmaceutical Companies Image Figure 17. Other Image Figure 18. Global Antiretroviral Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Antiretroviral Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Antiretroviral Drug Sales Value Share by Application (2021-2032) Figure 21. Global Antiretroviral Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Antiretroviral Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Antiretroviral Drug Sales Value (2021-2032) & (US$ Million) Figure 24. North America Antiretroviral Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Antiretroviral Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Antiretroviral Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Antiretroviral Drug Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Antiretroviral Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Antiretroviral Drug Sales Value (2021-2032) & (US$ Million) Figure 30. South America Antiretroviral Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Antiretroviral Drug Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Antiretroviral Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Antiretroviral Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Multi-Class Drugs Combination
  • Protease Inhibitors
  • NRTI
  • NNRTI
  • Other
Applications
  • Hospital
  • Pharmaceutical Companies
  • Other
Companies covered
  • Boehringer-Ingelheim
  • Bristol-Myer Squibb
  • CIPLA
  • Gilead Sciences
  • ViiV Healthcare
  • AbbVie
  • Merck
  • Johnson and Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antiretroviral Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antiretroviral Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Antiretroviral Drug Market Dynamics
  1. 2.1 Antiretroviral Drug Industry Trends
  2. 2.2 Antiretroviral Drug Industry Drivers
  3. 2.3 Antiretroviral Drug Industry Opportunities and Challenges
  4. 2.4 Antiretroviral Drug Industry Restraints
3 Antiretroviral Drug Market by Company
  1. 3.1 Global Antiretroviral Drug Company Revenue Ranking in 2025
  2. 3.2 Global Antiretroviral Drug Revenue by Company (2021-2026)
  3. 3.3 Global Antiretroviral Drug Company Ranking (2024-2026)
  4. 3.4 Global Antiretroviral Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Antiretroviral Drug Company Product Type and Application
  6. 3.6 Global Antiretroviral Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Antiretroviral Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Antiretroviral Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Antiretroviral Drug Market by Type
  1. 4.1 Antiretroviral Drug Type Introduction
  2. 4.1.1 Multi-Class Drugs Combination
  3. 4.1.2 Protease Inhibitors
  4. 4.1.3 NRTI
  5. 4.1.4 NNRTI
  6. 4.1.5 Other
  7. 4.2 Global Antiretroviral Drug Sales Value by Type
  8. 4.2.1 Global Antiretroviral Drug Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Antiretroviral Drug Sales Value by Type (2021-2032)
  10. 4.2.3 Global Antiretroviral Drug Sales Value Share by Type (2021-2032)
5 Antiretroviral Drug Market by Application
  1. 5.1 Antiretroviral Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmaceutical Companies
  4. 5.1.3 Other
  5. 5.2 Global Antiretroviral Drug Sales Value by Application
  6. 5.2.1 Global Antiretroviral Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antiretroviral Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Antiretroviral Drug Sales Value Share by Application (2021-2032)
6 Antiretroviral Drug Regional Value Analysis
  1. 6.1 Global Antiretroviral Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antiretroviral Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Antiretroviral Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Antiretroviral Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antiretroviral Drug Sales Value (2021-2032)
  7. 6.3.2 North America Antiretroviral Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Antiretroviral Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Antiretroviral Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Antiretroviral Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Antiretroviral Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Antiretroviral Drug Sales Value (2021-2032)
  16. 6.6.2 South America Antiretroviral Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Antiretroviral Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Antiretroviral Drug Sales Value Share by Country, 2025 VS 2032
7 Antiretroviral Drug Country-level Value Analysis
  1. 7.1 Global Antiretroviral Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antiretroviral Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Antiretroviral Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Antiretroviral Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Antiretroviral Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Antiretroviral Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Antiretroviral Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Boehringer-Ingelheim
  2. 8.1.1 Boehringer-Ingelheim Company Information
  3. 8.1.2 Boehringer-Ingelheim Business Overview
  4. 8.1.3 Boehringer-Ingelheim Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Boehringer-Ingelheim Antiretroviral Drug Product Portfolio
  6. 8.1.5 Boehringer-Ingelheim Recent Developments
  7. 8.2 Bristol-Myer Squibb
  8. 8.2.1 Bristol-Myer Squibb Company Information
  9. 8.2.2 Bristol-Myer Squibb Business Overview
  10. 8.2.3 Bristol-Myer Squibb Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myer Squibb Antiretroviral Drug Product Portfolio
  12. 8.2.5 Bristol-Myer Squibb Recent Developments
  13. 8.3 CIPLA
  14. 8.3.1 CIPLA Company Information
  15. 8.3.2 CIPLA Business Overview
  16. 8.3.3 CIPLA Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CIPLA Antiretroviral Drug Product Portfolio
  18. 8.3.5 CIPLA Recent Developments
  19. 8.4 Gilead Sciences
  20. 8.4.1 Gilead Sciences Company Information
  21. 8.4.2 Gilead Sciences Business Overview
  22. 8.4.3 Gilead Sciences Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Sciences Antiretroviral Drug Product Portfolio
  24. 8.4.5 Gilead Sciences Recent Developments
  25. 8.5 ViiV Healthcare
  26. 8.5.1 ViiV Healthcare Company Information
  27. 8.5.2 ViiV Healthcare Business Overview
  28. 8.5.3 ViiV Healthcare Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ViiV Healthcare Antiretroviral Drug Product Portfolio
  30. 8.5.5 ViiV Healthcare Recent Developments
  31. 8.6 AbbVie
  32. 8.6.1 AbbVie Company Information
  33. 8.6.2 AbbVie Business Overview
  34. 8.6.3 AbbVie Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AbbVie Antiretroviral Drug Product Portfolio
  36. 8.6.5 AbbVie Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Antiretroviral Drug Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Johnson and Johnson
  44. 8.8.1 Johnson and Johnson Company Information
  45. 8.8.2 Johnson and Johnson Business Overview
  46. 8.8.3 Johnson and Johnson Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Johnson and Johnson Antiretroviral Drug Product Portfolio
  48. 8.8.5 Johnson and Johnson Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst